S.C.P.C (1720) reported revenue of NT$619 million for Oct 2026, -3.5% year on year and -11.5% from the previous month. Revenue for Jan–Oct 2026 was NT$6.06 billion (+3.2% year on year).
In Oct 2026, it ranked No. 14 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$619 million | -3.5% | -11.5% |
| Sep 2026 | NT$699.6 million | +11.2% | +12.2% |
| Aug 2026 | NT$623.7 million | +7.8% | +4.4% |
| Jul 2026 | NT$597.2 million | +6.4% | -2.9% |
| Jun 2026 | NT$615 million | +9.1% | +5.9% |
| May 2026 | NT$581 million | -5.0% | -14.2% |
| Apr 2026 | NT$677.3 million | +3.8% | +18.8% |
| Mar 2026 | NT$570.2 million | +2.8% | +22.3% |
| Feb 2026 | NT$466.1 million | -16.4% | -24.2% |
| Jan 2026 | NT$614.9 million | +16.6% | +8.7% |
| Dec 2025 | NT$565.8 million | +4.8% | -2.1% |
| Nov 2025 | NT$578 million | -2.9% | -9.9% |
| Oct 2025 | NT$641.2 million | +19.4% | +1.9% |
| Sep 2025 | NT$629.4 million | +9.0% | +8.8% |
| Aug 2025 | NT$578.7 million | -2.3% | +3.1% |
| Jul 2025 | NT$561.5 million | -2.1% | -0.4% |
| Jun 2025 | NT$563.7 million | +0.2% | -7.8% |
| May 2025 | NT$611.7 million | +2.6% | -6.3% |
| Apr 2025 | NT$652.5 million | +8.6% | +17.6% |
| Mar 2025 | NT$554.7 million | +5.4% | -0.6% |
| Feb 2025 | NT$557.8 million | +25.4% | +5.8% |
| Jan 2025 | NT$527.5 million | -17.9% | -2.3% |
| Dec 2024 | NT$539.9 million | +7.3% | -9.3% |
| Nov 2024 | NT$595.1 million | +2.3% | +10.8% |
| Oct 2024 | NT$536.9 million | +5.4% | -7.0% |
Jan–Oct 2026 cumulative: NT$6.06 billion (+3.2% YoY)
Other Biotech & Medical companies
Compare with peers: S.C.P.C vs PEC / S.C.P.C vs Lotus Pharm / S.C.P.C vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16